Colitis Clinical Trials

334 recruitingLast updated: July 16, 2026

There are 334 actively recruiting colitis clinical trials across 66 countries. Studies span Not Applicable, Phase 2, Phase 3, Phase 1, Phase 4, Early Phase 1. Top locations include New York, New York, United States, Warsaw, Poland, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Colitis Trials at a Glance

334 actively recruiting trials for colitis are listed on ClinicalTrialsFinder across 6 cities in 66 countries. The largest study group is Not Applicable with 81 trials, with the heaviest enrollment activity in New York, Warsaw, and Houston. Lead sponsors running colitis studies include Takeda, AbbVie, and Eli Lilly and Company.

Treatments under study

About Colitis Clinical Trials

Looking for clinical trials for Colitis? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Colitis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Colitis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 334 trials

Recruiting
Phase 1

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

Breast CancerOvarian CancerCervical Cancer+6 more
M.D. Anderson Cancer Center40 enrolled1 locationNCT04038619
Recruiting
Phase 1

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

Malignant Solid NeoplasmClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8+41 more
M.D. Anderson Cancer Center800 enrolled1 locationNCT03819296
Recruiting
Phase 3

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis
Sanofi671 enrolled46 locationsNCT07185009
Recruiting
Not Applicable

Fecal Microbiota Transplantation in Pediatric Ulcerative Colitis (UC)

Ulcerative Colitis
Biao Zou30 enrolled1 locationNCT05679622
Recruiting

Immune Regulation in Ulcerative Colitis or Crohn s Disease

Ulcerative ColitisInflammatory Bowel DiseaseChrohn's Disease
National Institute of Allergy and Infectious Diseases (NIAID)1,000 enrolled1 locationNCT00001184
Recruiting
Phase 2

A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

Ulcerative ColitisColitis Ulcerative
Merck Sharp & Dohme LLC100 enrolled12 locationsNCT07463183
Recruiting
Not Applicable

Delayed Versus Immediate Cord Clamping in Preterm Birth

neonatal morbidity and mortalityDelayed cord clampingAnemia+5 more
Faculty of Medicine of Tunis200 enrolled1 locationNCT07699666
Recruiting
Not Applicable

BOOM-IBD2 Pivotal Clinical Trial

Inflammatory Bowel DiseasesUlcerative Colitis
Boomerang Medical137 enrolled19 locationsNCT06571669
Recruiting
Phase 2

A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

Ulcerative Colitis
Pfizer36 enrolled45 locationsNCT05287126
Recruiting

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

Ulcerative Colitis (UC)Crohn Disease (CD)Inflammatory Bowel Disease (IBD)+1 more
TIDHI Innovation Inc.200 enrolled12 locationsNCT07245394
Recruiting
Phase 2

Confirmatory Clinical Study in Active Ulcerative Colitis

Colitis Ulcerative
MRM Health NV204 enrolled16 locationsNCT07296315
Recruiting
Phase 4

A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

Ulcerative Colitis
Takeda65 enrolled49 locationsNCT06095128
Recruiting

An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis

Colitis Ulcerative
Pfizer300 enrolled28 locationsNCT06398626
Recruiting

NAZA - Nottingham/Astra ZenecA Prospective IBD Cohort Study

Inflammatory Bowel DiseasesCrohn DiseaseUlcerative Colitis+1 more
University of Nottingham240 enrolled1 locationNCT06956703
Recruiting
Phase 2

A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

Crohn DiseaseColitis Ulcerative
Eli Lilly and Company60 enrolled71 locationsNCT07483073
Recruiting
Phase 4

Stopping PPI Therapy in Inactive IBD

Crohn's DiseaseUlcerative Colitis (UC)
University of Nottingham80 enrolled1 locationNCT07691138
Recruiting
Phase 3

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Ulcerative ColitisObesity or Overweight
Eli Lilly and Company350 enrolled189 locationsNCT06937086
Recruiting
Phase 2

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

Ulcerative Colitis
Eli Lilly and Company252 enrolled149 locationsNCT07186101
Recruiting
Phase 2

LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis (UC)Ulcerative Colitis, Active ModerateUlcerative Colitis, Active Severe
Eli Lilly and Company1,431 enrolled256 locationsNCT07415044
Recruiting

A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants

Arthritis, RheumatoidColitis Ulcerative
Eisai Korea Inc.2,040 enrolled59 locationsNCT06246123